These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33482290)

  • 1. Nonclinical & clinical interface - extrapolation of nonclinical data to support Phase I clinical studies.
    Baldrick P; Reichl A
    Regul Toxicol Pharmacol; 2021 Apr; 121():104869. PubMed ID: 33482290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Getting a molecule into the clinic: Nonclinical testing and starting dose considerations.
    Baldrick P
    Regul Toxicol Pharmacol; 2017 Oct; 89():95-100. PubMed ID: 28751261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose.
    Contrera JF; Matthews EJ; Kruhlak NL; Benz RD
    Regul Toxicol Pharmacol; 2004 Dec; 40(3):185-206. PubMed ID: 15546675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extrapolation of Oligonucleotide Dose Levels Used in Nonclinical Toxicity Studies to Selection of Safe Starting Dose Levels in Human Clinical Trials.
    Kornbrust D
    Nucleic Acid Ther; 2019 Jun; 29(3):123-125. PubMed ID: 30817231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials.
    Hansen AR; Cook N; Ricci MS; Razak A; Le Tourneau C; McKeever K; Roskos L; Dixit R; Siu LL; Hinrichs MJ
    Oncologist; 2015 Jun; 20(6):653-9. PubMed ID: 25964306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics.
    Agoram BM
    Br J Clin Pharmacol; 2009 Feb; 67(2):153-60. PubMed ID: 19076987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development.
    Ivens IA; Achanzar W; Baumann A; Brändli-Baiocco A; Cavagnaro J; Dempster M; Depelchin BO; Rovira AR; Dill-Morton L; Lane JH; Reipert BM; Salcedo T; Schweighardt B; Tsuruda LS; Turecek PL; Sims J
    Toxicol Pathol; 2015 Oct; 43(7):959-83. PubMed ID: 26239651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicology Paradise: Sorting Out Adverse and Non-adverse Findings in Animal Toxicity Studies.
    Baldrick P; Cosenza ME; Alapatt T; Bolon B; Rhodes M; Waterson I
    Int J Toxicol; 2020; 39(5):365-378. PubMed ID: 32618214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vivo Hypoglycemic Studies of Polyherbal Phytoceuticals, Their Pharmacokinetic Studies and Dose Extrapolation by Allometric Scaling.
    De B; Bhandari K; Katakam P; Mitra A
    Curr Drug Discov Technol; 2017; 14(4):277-292. PubMed ID: 28359233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NOEL and NOAEL: A retrospective analysis of mention in a sample of recently conducted safety pharmacology studies.
    Baird TJ; Caruso MJ; Gauvin DV; Dalton JA
    J Pharmacol Toxicol Methods; 2019; 99():106597. PubMed ID: 31220592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative evaluation of US Food and Drug Administration and pharmacologically guided approaches to determine the maximum recommended starting dose for first-in-human clinical trials in adult healthy men.
    Imam MT; Venkateshan SP; Tandon M; Saha N; Pillai KK
    J Clin Pharmacol; 2011 Dec; 51(12):1655-64. PubMed ID: 21415286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of the relationship between a starting dose in first-in-human studies and no observed adverse effect level in nonclinical studies.
    Sato A; Narukawa M
    Int J Clin Pharmacol Ther; 2014 Sep; 52(9):770-6. PubMed ID: 25034619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a role for the no observed adverse effect level in safety pharmacology?
    Mow T; Andersen NK; Dragsted N; Lassen AB; Laursen M; Bass AS; Valentin JP; Markgraf C; Authier S; Baird TJ; Bhatt S; Traebert M; Leishman DJ; Jones D; Curtis MJ
    J Pharmacol Toxicol Methods; 2020 Sep; 105():106917. PubMed ID: 32866658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
    Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
    Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research tools for extrapolating the disposition and pharmacokinetics of nanomaterials from preclinical animals to humans.
    Valic MS; Zheng G
    Theranostics; 2019; 9(11):3365-3387. PubMed ID: 31244958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current nonclinical testing paradigms in support of safe clinical trials: An IQ Consortium DruSafe perspective.
    Butler LD; Guzzie-Peck P; Hartke J; Bogdanffy MS; Will Y; Diaz D; Mortimer-Cassen E; Derzi M; Greene N; DeGeorge JJ
    Regul Toxicol Pharmacol; 2017 Jul; 87 Suppl 3():S1-S15. PubMed ID: 28483710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Silico Models for Repeated-Dose Toxicity (RDT): Prediction of the No Observed Adverse Effect Level (NOAEL) and Lowest Observed Adverse Effect Level (LOAEL) for Drugs.
    Pizzo F; Benfenati E
    Methods Mol Biol; 2016; 1425():163-76. PubMed ID: 27311467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current strategies in the non-clinical safety assessment of biologics: New targets, new molecules, new challenges.
    Brennan FR; Andrews L; Arulanandam AR; Blumel J; Fikes J; Grimaldi C; Lansita J; Loberg LI; MacLachlan T; Milton M; Parker S; Tibbitts J; Wolf J; Allamneni KP
    Regul Toxicol Pharmacol; 2018 Oct; 98():98-107. PubMed ID: 30026135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonclinical Safety Assessment of PER977: A Small Molecule Reversal Agent for New Oral Anticoagulants and Heparins.
    Sullivan DW; Gad SC; Laulicht B; Bakhru S; Steiner S
    Int J Toxicol; 2015; 34(4):308-17. PubMed ID: 26079256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug development and nonclinical to clinical translational databases: past and current efforts.
    Monticello TM
    Toxicol Pathol; 2015 Jan; 43(1):57-61. PubMed ID: 25389276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.